REGISTERED NUMBER: 03936112 (England and Wales)

Unaudited Financial Statements

for the Period 1 April 2024 to 31 December 2024

for

Jointmedica Limited

Page

Company Information

1

Chartered Accountants' Report

2

Balance Sheet

3

Notes to the Financial Statements

5

DIRECTOR:

Dr S K Kusuma

REGISTERED OFFICE:

Brook House

Moss Grove

Kingswinford

West Midlands

DY6 9HS

REGISTERED NUMBER:

03936112 (England and Wales)

ACCOUNTANTS:

Wilkes Tranter & Co Limited

Brook House

Moss Grove

Kingswinford

West Midlands

DY6 9HS

The following reproduces the text of the report prepared for the director in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Director's Report are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Jointmedica Limited for the period ended 31 December 2024 which comprise the Profit and Loss Account, Balance Sheet and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the director of Jointmedica Limited in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Jointmedica Limited and state those matters that we have agreed to state to the director of Jointmedica Limited in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Jointmedica Limited and its director for our work or for this report.

It is your duty to ensure that Jointmedica Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Jointmedica Limited. You consider that Jointmedica Limited is exempt from the statutory audit requirement for the period.

We have not been instructed to carry out an audit or a review of the financial statements of Jointmedica Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Wilkes Tranter & Co Limited

Brook House

Moss Grove

Kingswinford

West Midlands

DY6 9HS

26 September 2025

FIXED ASSETS

Intangible assets

4

104,953

96,297

Tangible assets

5

607,665

220,993

Investments

6

57,754

57,420

770,372

374,710

CURRENT ASSETS

Stocks

1,024,482

734,610

Debtors

7

1,407,285

883,573

Cash at bank and in hand

11,022,963

15,109,278

13,454,730

16,727,461

CREDITORS

Amounts falling due within one year

8

(1,148,736

)

(485,593

)

NET CURRENT ASSETS

12,305,994

16,241,868

TOTAL ASSETS LESS CURRENT LIABILITIES

13,076,366

16,616,578

CAPITAL AND RESERVES

Called up share capital

25,854

25,854

Share premium

20,089,370

20,089,370

Capital contribution

4,674,000

4,674,000

Retained earnings

(11,712,858

)

(8,172,646

)

13,076,366

16,616,578

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the director and authorised for issue on 26 September 2025 and were signed by:

Dr S K Kusuma - Director

1.	STATUTORY INFORMATION

Jointmedica Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences are being amortised evenly over their estimated useful life of twenty years.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Improvements to property

-

33% on cost

Plant and machinery

-

at varying rates on cost

Fixtures and fittings

-

50% on cost

Computer equipment

-

at varying rates on cost

Investments in subsidiaries

Investments in subsidiary undertakings are recognised at cost.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

Taxation for the period comprises current and deferred tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the period was 22 (2024 - 16 ) .

4.	INTANGIBLE FIXED ASSETS

Patents

and

licences

£

COST

At 1 April 2024

126,000

Additions

13,902

At 31 December 2024

139,902

AMORTISATION

At 1 April 2024

29,703

Amortisation for period

5,246

At 31 December 2024

34,949

NET BOOK VALUE

At 31 December 2024

104,953

At 31 March 2024

96,297

5.	TANGIBLE FIXED ASSETS

Improvements

Fixtures

to

Plant and

and

Computer

property

machinery

fittings

equipment

Totals

£

£

£

£

£

COST

At 1 April 2024

17,733

960,715

11,085

81,764

1,071,297

Additions

235,165

211,465

12,404

14,551

473,585

At 31 December 2024

252,898

1,172,180

23,489

96,315

1,544,882

DEPRECIATION

At 1 April 2024

12,315

767,467

7,098

63,424

850,304

Charge for period

29,938

42,617

3,507

10,851

86,913

At 31 December 2024

42,253

810,084

10,605

74,275

937,217

NET BOOK VALUE

At 31 December 2024

210,645

362,096

12,884

22,040

607,665

At 31 March 2024

5,418

193,248

3,987

18,340

220,993

6.	FIXED ASSET INVESTMENTS

Shares in

group

undertakings

£

COST

At 1 April 2024

57,420

Additions

334

At 31 December 2024

57,754

NET BOOK VALUE

At 31 December 2024

57,754

At 31 March 2024

57,420

7.

DEBTORS

2024

2024

£

£

Amounts falling due within one year:

Trade debtors

153,596

60,219

Other debtors

434,740

245,756

588,336

305,975

2024

2024

£

£

Amounts falling due after more than one year:

Amounts owed by group undertakings

818,949

577,598

Aggregate amounts

1,407,285

883,573

8.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2024

2024

£

£

Trade creditors

222,880

198,788

Taxation and social security

46,668

36,389

Other creditors

879,188

250,416

1,148,736

485,593

9.	ULTIMATE CONTROLLING PARTY

The company was under the control of its directors throughout the current and previous year.

The ultimate parent undertaking is TPG,INC registered in Delaware, United States by virtue of holding a controlling shareholding in the company.